Team
Our team combines decades of drug development experience, single cell computational biology expertise, and a background in pathogenic cell elimination.
Adam Freund, PhD
Founder & Chief Executive Officer
Dr. Freund has 20 years of experience in life science R&D, focused on blending experimental and computational biology to understand and modulate chronic diseases. He has published >20 papers and patents, which have been cited >10,000 times. Prior to founding Arda, he was a Principal Investigator at Calico Life Sciences, where he helped grow the company from ~15 to 200+ employees and initiated and led multiple therapeutic programs, several of which are now in the clinic.
Scott Turner, PhD
Chief Scientific Officer
Dr. Turner is a globally recognized leader in the development and translation of anti-fibrotic therapies. With over 20 years of drug development experience, Dr. Turner has made remarkable advancements, most recently at Pliant Therapeutics, where he served as CSO and led development of their primary asset, culminating in a successful Phase 2a for idiopathic pulmonary fibrosis (IPF). While at Pliant he also developed novel PK/PD approaches to assess drug activity in IPF patients and led the discovery and development of novel therapeutics for oncology and Duchenne muscular dystrophy, both of which are now in the clinic. Prior to Pliant, he led research and development for KineMed Inc. a biomarker platform company which specialized in utilizing stable isotopes to quantify in vivo the flux of macro molecules in health and disease.
Remi-Martin Laberge, PhD
Co-founder and Chief Technology Officer
Dr. Laberge has 20+ years of experience in life science R&D. He is an expert in pathogenic cell elimination, discovered the first senolytic molecules, and has published >50 papers and patents. Prior to Arda, he was Head of Cellular Biology at Unity Biotechnology, where he drove platform development and led multiple teams to clinical stage assets. As part of the foundational team at Unity, he grew the company from inception to >100 employees. He was also previously the VP of Scientific Operations at IRICoR, where he managed a portfolio of >20 early drug discovery programs.